Repare Therapeutics Inc. announced a re-alignment of resources and a re-prioritization of its clinical portfolio to focus on the continued advancement of its Phase 1 clinical programs, RP-1664 and RP-3467. This strategic shift aims to maximize value creation.
The company intends to seek partnering opportunities for lunresertib and camonsertib (Lunre+Camo) prior to any start of pivotal development, despite positive Phase 1 results. This decision, combined with planned cost and headcount reductions, is expected to extend Repare’s cash runway into mid-2027.
Repare ended 2024 with approximately $153 million in cash, cash equivalents, and marketable securities. Initial clinical readouts for RP-1664 and RP-3467 are expected to begin in Q3 2025, representing key near-term catalysts for the company.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.